Naphthoquinones from Onosma paniculata Induce Cell-Cycle Arrest and Apoptosis
in Melanoma Cells by Kretschmer, Nadine et al.
Naphthoquinones from Onosma paniculata Induce Cell-Cycle Arrest
and Apoptosis in Melanoma Cells
Nadine Kretschmer,
† Beate Rinner,
‡ Alexander J. A. Deutsch,
§ Birgit Lohberger,
⊥ Heike Knausz,
‡
Olaf Kunert,
∥ Martina Blunder,
† Herbert Boechzelt,
∇ Helmut Schaider,
# and Rudolf Bauer*
,†
†Department of Pharmacognosy, Institute of Pharmaceutical Sciences, Karl-Franzens University, Graz 8010, Austria
‡Core Facility Flow Cytometry, Center for Medical Research, Medical University of Graz, Graz 8010, Austria
§Department of Hematology, Internal Medicine, Medical University Graz, Graz 8036, Austria
⊥Department of Orthopaedic Surgery, Medical University of Graz, Graz 8036, Austria
∥Department of Pharmaceutical Chemistry, Institute of Pharmaceutical Sciences, Karl-Franzens University, Graz 8010, Austria
∇Joanneum Research Forschungsgesellschaft mbH, Graz 8010, Austria
#Department of Dermatology and Center for Medical Research, Cancer Biology Unit, Medical University of Graz, Graz 8036, Austria
* S Supporting Information
ABSTRACT: Activity-guided fractionation of a petroleum
ether-soluble extract of the roots of Onosma paniculata, which
has been shown to aﬀect the cell cycle and to induce apoptosis
in melanoma cells, led to the isolation of several shikonin
derivatives, namely, β-hydroxyisovalerylshikonin (1), acetyl-
shikonin (2), dimethylacrylshikonin (3), and a mixture of α-
methylbutyrylshikonin and isovalerylshikonin (4+5). All
compounds exhibited strong cytotoxicity against eight cancer
cell lines and MRC-5 lung ﬁbroblasts, with 3 found to possess
the most potent cytotoxicity toward four melanoma cell lines
(SBcl2, WM35, WM9, and WM164). Furthermore, 3 and the mixture of 4+5 were found to interfere with cell-cycle progression
in these cell lines and led to an increasing number of cells in the subG1 region as well as to caspase-3/7 activation, indicating
apoptotic cell death.
O
nosma paniculata Bureau & Franchet is a biennial herb
belonging to the family Boraginaceae. The genus Onosma
is represented by 145 species centered in Asia, out of which 29
species are found in mainland China.
1 The dried roots of this
(“Dian Zi Cao”) and related species (e.g., Arnebia euchroma
[“Ruan Zi Cao”], Lithospermum erythrorhizon [“Ying Zi Cao”])
are used in traditional Chinese medicine for the treatment of
various diseases including cancer.
2,3 Shikonin and alkannin
derivatives are the main constituents and are found in at
least 150 species of Boraginaceous genera including Litho-
spermum, Echium,a n dOnosma.
4 Their pharmacological
activities range from wound-healing to anti-inﬂammatory,
anticancer, and antimicrobial and antiviral properties.
5−16
However, O. paniculata is presently little investigated regard-
ing its constituents and pharmacological activities. In a pre-
vious study by our group, it was shown that a petroleum
ether extract of the roots exhibited strong growth inhibitory
activity toward cancer cell lines and induced cell death
caspase-dependently.
17 We now have undertaken bioassay-
guided fractionation and report the isolation and structure
elucidation of the active principles and their eﬀects on cancer
cell lines.
■ RESULTS AND DISCUSSION
HPLC analysis of the active petroleum ether-soluble extract
pointed to several shikonin derivatives.
17 Using preparative
HPLC, seven fractions were collected, from which fractions 2,
4, 6, and 7 gave β-hydroxyisovalerylshikonin (1), acetylshikonin
(2), dimethylacrylshikonin (3), and a mixture of α-methyl-
butyrylshikonin (4) and isovalerylshikonin (5), respectively.
Since it has been demonstrated that biological activity can be
lost due to polymerization during isolation processes,
4 the one-
step isolation procedure used was a great beneﬁt in the present
work. The isolates were identiﬁed using 1H and 13C NMR and
CD spectroscopic measurements (Tables S1 and S2,
Supporting Information) and by comparison with published
data.
12,18 Compounds 4+5 were obtained as a mixture and
could not be separated, but 1H and 13C NMR data clearly
revealed them to occur in a ratio of 2:1. The enantiomers
shikonin and alkannin give identical NMR spectra
19 but vary in
conﬁguration at C-11. They are not capable of being
diﬀerentiated by optical rotation with a sodium lamp as light
source, but CD measurements may be used for this purpose. All
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identiﬁed as shikonin derivatives.
19,20 This is the ﬁrst report
concerning the CD data of 1−3.
Subsequently, the compounds were evaluated for their
cytotoxic potential using eight human cancer cell lines and
human nontumorigenic MRC-5 lung ﬁbroblasts. Cytotoxicity
was compared to vinblastine, which was used as positive control
(Table 1). All isolated compounds exhibited cytotoxicity with
IC50 values ranging from 600 nM to 70 μM. The most sensitive
was the CCRF-CEM leukemia cell line, showing up to 6-fold
lower IC50 values than MRC-5 cells. The four melanoma cell
lines (SBcl2, WM35, WM9, and WM164) were isolated
primarily from diﬀerent stages of melanoma progression.
21 It
has been shown that numerous genetic mutations leading to
altered cell signaling are involved in the transformation from
benign nevi to melanoma.
22 These changes enable melanoma
cells to escape apoptosis and contribute to unrestricted cell
proliferation. The eﬀects of 3 and the mixture of 4+5 regarding
cell morphology, cell-cycle distribution, and apoptosis
induction were analyzed. Test compounds were freshly
dissolved in DMSO and used immediately since storage in
DMSO led to a considerable loss of activity. Compound 3
exhibited the lowest IC50 values toward melanoma cell lines,
which is probably due to the presence of an unsaturated
carbonyl group in the side chain. Morphological changes
(Figure S3, Supporting Information) were observed after 24 h
and continued up to 48 h. Cells exposed to the IC50
concentrations of 3 or 4+5 exhibited less density and a more
round shape phenotype with fewer dendrites. It has been
reported that shikonin induces apoptosis in several cell
lines
23−25 and aﬀects the cell cycle.
24,26 However, compound
3 and 4+5 are less well investigated. Investigations of the cell-
cycle distribution revealed that 3 and 4+5 strongly aﬀected the
amount of cells in the G1 phase and, accordingly, the G2/M or
S phase. For 3, it was found that there were up to 50% fewer
cells in the G1 phase and an increasing number of cells in the S
phase (SBcl2 and WM35) or G2/M phase (WM9 and
WM164) (Figure 1). In contrast to 3 and also 4+5, shikonin
led to an arrest in the G1 phase in melanoma
26 and bladder
24
cancer cells, while cells in the G2/M phase decreased,
indicating a diﬀerent mode of action. Additionally, cells in the
subG1 region (up to about 20%) increased after 24 h (up to ca.
20%), indicating apoptotic cell death, which was conﬁrmed
using a CaspaseGlo 3/7 assay (Figure 2). The results for cells
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Supporting Information).
In summary, it has been shown that roots of O. paniculata are
a rich source of acetylshikonin (2), dimethylacrylshikonin (3),
α-methylbutyrylshikonin (4), and isovalerylshikonin (5). All of
these compounds exhibited cytotoxicity toward a panel of
cancer cell lines. For the melanoma cell lines used, the results
indicated that 3 and the mixture of 4+5 aﬀect the cell cycle and
induce apoptosis.
■ EXPERIMENTAL SECTION
General Experimental Procedures. CD measurements were
recorded on a JASCO J-715 spectropolarimeter, at 210−600 nm in
CHCl3. NMR spectra were recorded in chloroform-d1 (Eurisotop,
Saint-Aubin Cedex, France) on a Varian Unitylnova 400 MHz (400 MHz
for 1H and 100 MHz for 13C) or 600 MHz (600 MHz for 1H and
150 MHz for 13C) spectrometer at 25 °C using TMS as internal
standard. For analytical HPLC experiments, a LiChroCART RP18
column (250 × 4 mm, 5 μm) and a Merck Hitachi system consisting
of an L-7100 pump, L-7200 autosampler, L-7455 diode array detector,
and a D-7000 interface were used. Preparative reversed-phase HPLC
was performed on a Varian R PrepStar SD-1 with Dynamax R solvent
delivery system and an absorbance detector model UV-1 using a
VDSpher 100 RP18 column (250 × 25 mm, 10 μm). For both, the
mobile phase consisted of water (A) and ACN (B). The following
gradient was used: 0−45 min, 70−100% B; 45−60 min, 100% B.
Plant Material. The dried roots of O. paniculata were purchased at
a medicinal plant market in Kunming, China, in November 2003. They
were identiﬁed macroscopically by Prof. Xiao-Jiang Hao, and the
identity was conﬁrmed based on its ITS and trnL-F regions by Prof.
Guenther Heubl as described previously.
17 A voucher specimen is
deposited at the herbarium of the Institute for Plant Sciences, University of
Graz, Austria.
Extraction and Isolation. The petroleum ether extract was
prepared by Soxhlet extraction.
17 A 400 mg aliquot of this extract was
dissolved in MeOH (40 mg/mL) and fractionated using preparative
HPLC. Seven fractions were collected, from which fractions 2, 4, 6,
and 7 gave 1 (1.1 mg), 2 (31.1 mg), 3 (48.6 mg), and 4+5 (46.3 mg),
respectively.
β-Hydroxyisovalerylshikonin (1): red powder; CD (c 2.5 mM,
CHCl3)[ θ]315 −15450, [θ]365 +15 910; 1H NMR (CDCl3, 400 MHz)
data, see Table S1 Supporting Information; 13CN M R( C D C l 3,
100 MHz) data, see Table S2 Supporting Information.
Acetylshikonin (2): red powder; CD (c 5.0 mM, CHCl3)[ θ]305
−1470, [θ]356 +1650; 1H NMR (CDCl3, 600 MHz) data, see Table S1
Supporting Information; 13CN M R( C D C l 3, 150 MHz) data, see Table S2
Supporting Information.
Dimethylacrylshikonin (3): red powder; CD (c 4.0 mM, CHCl3)
[θ]315 −990, [θ]359 +540; 1H NMR (CDCl3, 400 MHz) data, see
Table S1 Supporting Information.
α-Methylbutyrylshikonin (4) and Isovalerylshikonin (5): red
powder; 1H NMR (CDCl3, 600 MHz) data, see Table S1 Supporting
Figure 1. Treatment of melanoma cells with 3 reduced cells in the G1 phase and increased cells especially in the S-phase (SBcl2 (A) and WM35
(B)), and G2/M phase (WM9 (C) and WM164 (D)). Gray bars: Vehicle-treated control cells. Colored bars: Cells exposed to 3 (IC50). The times
shown represent the duration of treatment, n = 3, with mean values shown. Areas from the bottom to the top: subG1 cells (black and purple), G1
phase cells (lower light gray and blue), S phase cells (dark gray and turquoise), and G2/M phase cells (upper light gray and green).
Figure 2. Caspase 3/7 activity measured using the Caspase-Glo 3/7
assay. Caspase activity peaked after 24 h when cells were exposed to
the IC50 value of 3, indicating apoptotic cell death.
Journal of Natural Products Article
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Supporting Information.
Sample Preparation. The compounds were freshly dissolved in
DMSO, subsequently diluted with medium, and used immediately.
Control cells represent vehicle-treated cells (0.5% DMSO). The ﬁnal
DMSO concentration did not aﬀect the cells.
Cell Culture. Human CCRF-CEM leukemia and MDA-MB-231
breast cancer cells lines were maintained in RPMI 1640 medium
(Sigma-Aldrich, St. Louis, MO, USA), supplemented with 2 mM
L-glutamine (Sigma-Aldrich), 10% fetal bovine serum (FBS, PAA
Laboratories, Pasching, Austria), 100 units/mL penicillin (PAA), and
100 μg/mL streptomycin (PAA) (1% penicillin/streptomycin).
Human U251 glioblastoma and HCT 116 colon cancer cell lines
were grown in high-glucose Dulbecco's modiﬁed Eagle medium
(DMEM, Sigma-Aldrich) supplemented with 2 mM L-glutamine, 10%
FBS, and 1% penicillin/streptomycin. Human SBcl2, WM35, WM9,
and WM164 melanoma cell lines were grown in RPMI 1640 medium
with 2 mM L-glutamine, 2% FBS, and 1% penicillin/streptomycin.
Human MRC-5 lung ﬁbroblasts were grown in minimum essential
medium (MEM, Gibco, Invitrogen, Vienna, Austria) supplemented
with 2 mM L-glutamine, 10% FBS, and 1% penicillin/streptomycin. All
cells were kept in a humidiﬁed 5% CO2 atmosphere at 37 °C and
passaged at 90% conﬂuence. The cell cultures were periodically
checked for the presence of mycoplasma by PCR.
XTT Viability Assay. The XTT viability assay was performed as
described previously
17 and in accordance with the manufacturer's
protocol (Roche Diagnostics, Mannheim, Germany; cell proliferation
kit II (XTT), cat. no 11 465 015 001). In brief, 10000 cells/well in the
case of CCRF-CEM and MRC-5 cells and 5000 cells/wells for the
other cell lines were seeded into 96-well plates (100 μL, ﬂat bottom)
and treated with various concentrations of 1−3 or 4+5 for 72 h.
Adherent cell lines were grown overnight before the test compounds
were added. After 72 h, a freshly prepared XTT solution (5 mL of
XTT plus 100 μL of electron coupling reagent) was added and
analyzed after another 1.5 or 4 h (CCRF-CEM cells) using a Victor2
1420 multilabel counter (PerkinElmer Life Sciences, Waltham, MA,
USA). Vinblastine served as positive control (0.01 μM).
Cell-Cycle Analysis. Cells were treated with the respective IC50
concentration for 12−72 h and harvested by trypsinization. Then, 5 ×
105 cells were ﬁxed with 70% ice-cold EtOH for 10 min at 4 °C. After
washing with PBS, the cell pellet was resuspended in propidium iodide
(PI) staining buﬀer (50 μL/mL PI, RNase A, Beckman Coulter,
Krefeld, Germany) and incubated at 37 °C for 15 min. Cell-cycle
distribution was analyzed using a FACSCalibur ﬂow cytometer (BD
Biosciences, Heidelberg, Germany) using Modﬁt Software version 3.0
(Verity Software House, Topsham, ME, USA).
Caspase-Glo 3/7Assay. For this assay, 10 000 cells/well (100 μL)
were treated with the respective test-compound IC50 concentration for
6−72 h and analyzed for caspase activation using the Caspase-Glo 3/7
assay (Promega Corporation, Madison, WI, USA), according to the
manufacturer's protocol. Luminescence was measured 30 min after
adding the Caspase-Glo 3/7 reagent (Caspase-Glo substrate and
buﬀer).
Statistical Analysis. Statistical analysis was carried out using
SigmaPlot 12.0 (Systat Software Inc., Chicago, IL, USA). IC50 values
were determined using the four-parameter logistic curve, at least eight
concentrations of the test compound, and two diﬀerent cell passages
each tested in three independent wells. Results are expressed as mean
± SEM.
■ ASSOCIATED CONTENT
* S Supporting Information
1H and 13C NMR spectroscopic data of 1−5, photographs of
morphological changes (24 and 48 h) caused by 3 and 4+5,a s
well as the eﬀects of compounds 4 +5 on the cell-cycle (12−72 h)
distribution and activation of caspase 3/7 (6−72 h). This
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